Clinical Scorecard: Short-Term Use of Selective COX-2 Inhibitors for Musculoskeletal Pain Management in Patients with Remission of Inflammatory Bowel Disease: A Narrative Review
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD)
Key Mechanisms
Selective COX-2 inhibitors reduce upper GI ulceration by preferentially inhibiting COX-2 while sparing COX-1.
Target Population
Patients with IBD in remission experiencing musculoskeletal pain.
Care Setting
Clinical management of musculoskeletal symptoms in patients with IBD.
Key Highlights
Short-term selective COX-2 inhibitors may be used for musculoskeletal pain in IBD patients in remission.
Two placebo-controlled trials showed no higher rates of IBD relapse vs placebo during short-term treatment.
Open-label studies reported variable GI adverse events and symptom worsening.
Treatment should be time-limited and use the lowest effective dose.
Routine safety assessment is required due to potential cardiovascular risks.
Guideline-Based Recommendations
Diagnosis
Evaluate musculoskeletal symptoms in patients with IBD.
Management
Consider short-term use of selective COX-2 inhibitors for pain management in IBD patients in remission.
Monitoring & Follow-up
Include clinical monitoring for gastrointestinal and cardiovascular safety.
Risks
Monitor for potential gastrointestinal injury and cardiovascular risks associated with COX-2 inhibitors.
Patient & Prescribing Data
Patients with inflammatory bowel disease in remission.
Cautious use of selective COX-2 inhibitors is supported for managing musculoskeletal pain.
Clinical Best Practices
Limit the duration of COX-2 inhibitor therapy.
Use the lowest effective dose for pain management.
Conduct routine safety assessments during treatment.
